| Literature DB >> 25918718 |
Serife Gokbulut Bektas1, Sema Turan2, Umit Karadeniz1, Burcin Ozturk1, Soner Yavas3, Dilan Biricik4, Gul Sevim Saydam4, Ozcan Erdemli1.
Abstract
BACKGROUND: Our study aimed to compare HTEA and intravenous patient-controlled analgesia (PCA) in patients undergoing coronary bypass graft surgery (CABG), based on haemodynamic parameters and myocardial functions.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25918718 PMCID: PMC4395980 DOI: 10.1155/2015/658678
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Distribution of demographic characteristics of groups.
| Group 1 | Group 2 |
| |
|---|---|---|---|
| Age | 56 ± 8.4 | 54 ± 7.4 | NS |
|
| |||
| Gender | |||
| Female | 6 (54.5) | 4 (23.5) | NS |
| Male | 11 (45.5) | 13 (76.5) | |
|
| |||
| BSA | 1.83 ± 0.14 | 1.89 ± 0.16 | NS |
| Body weight | 75 ± 11.3 | 80 ± 12.0 | |
|
| |||
| EF | 57 ± 5.0 | 54 ± 5.2 | NS |
|
| |||
| HT | 4 (23.5) | 7 (41.1) | NS |
| DM | 5 (71.4) | 2 (11.7) | NS |
| COPD | 1 (5.8) | 2 (11.7) | NS |
| Thyroid dysfunction | 2 (11.7) | 0 | NS |
| CVD | 1 (5.8) | 0 | NS |
| Smoking | 2 (11.7) | 5 (71.4) | NS |
|
| |||
| Preoperative drug history | |||
|
| 3 (17.6) | 3 (17.6) | NS |
| CCBs | 0 | 1 (5.8) | NS |
| Nitrates | 4 (23.5) | 3 (17.6) | NS |
| ACEIs | 3 (17.6) | 3 (17.6) | NS |
|
| |||
| Mortality | — | — | — |
|
| |||
| Complications | — | — | — |
BSA: body surface area, EF: ejection fraction, HT: hypertension, DM: diabetes mellitus, COPD: chronic obstructive pulmonary disease, CVD: cerebrovascular disease, CCB: calcium channel blocker, ACEI: angiotensin converting enzyme inhibitor, and NS: not significant.
The systemic and pulmonary hemodynamic parameters.
| t1 | t2 | t3 | t4 | t5 | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Cardiac index (L·min−1·m−2) | |||||
| Group 1 | 2.13 ± 0.57 | 2.58 ± 0.72 | 2.36 ± 0.70 | 2.75 ± 0.66+ | 2.81 ± 0.62+ |
| Group 2 | 2.22 ± 0.66 | 3.09 ± 0.64∗+ | 2.92 ± 0.73∗+ | 3.37 ± 0.44∗+ | 3.25 ± 0.14∗+ |
| Mean arterial pressure (mmHg) | |||||
| Group 1 | 77.3 ± 11.21 | 67.8 ± 6.88+ | 74.0 ± 9.20 | 78.4 ± 10.69 | 76.5 ± 6.30 |
| Group 2 | 75.8 ± 13.53 | 65.9 ± 8.42+ | 67.3 ± 9.11∗+ | 70.1 ± 9.66* | 70.5 ± 4.95* |
| Central venous pressure (mmHg) | |||||
| Group 1 | 8.88 ± 1.57 | 9.35 ± 2.31 | 9.17 ± 2.32 | 8.78 ± 0.96 | 8.97 ± 0.78 |
| Group 2 | 8.47 ± 1.05 | 8.82 ± 2.03 | 8.55 ± 1.83 | 8.56 ± 0.93 | 8.60 ± 0.93 |
| Heart rate (beats/min) | |||||
| Group 1 | 69.8 ± 12.83 | 85.4 ± 12.42+ | 85.8 ± 14.71+ | 93.5 ± 18.45+ | 92.3 ± 14.83+ |
| Group 2 | 69.9 ± 10.23 | 67.7 ± 9.09* | 67.4 ± 9.15* | 69.7 ± 9.26* | 72.9 ± 4.65* |
| Mean pulmonary artery pressure (mmHg) | |||||
| Group 1 | 21.7 ± 5.59 | 22.0 ± 5.50 | 21.2 ± 5.69 | 21.2 ± 6.28 | 20.4 ± 5.93 |
| Group 2 | 19.7 ± 4.38 | 20.4 ± 3.28 | 20.1 ± 4.18 | 19.5 ± 3.87 | 20.1 ± 4.49 |
| Pulmonary capillary wedge pressure (mmHg) | |||||
| Group 1 | 16.2 ± 4.57 | 16.2 ± 4.46 | 16.4 ± 4.59 | 15.7 ± 5.66 | 15.7 ± 5.46 |
| Group 2 | 15.5 ± 4.00 | 15.4 ± 4.18 | 15.1 ± 3.62 | 14.5 ± 4.51 | 15.4 ± 4.21 |
| Systemic vascular resistance (dyne·sec/cm5) | |||||
| Group 1 | 520.8 ± 126.3 | 419.3 ± 101.7 | 460.1 ± 111.5 | 354.2 ± 85.9 | 414.3 ± 100.5 |
| Group 2 | 486.5 ± 117.9 | 212.5 ± 51.5* | 256.8 ± 62.2* | 230.2 ± 55.8* | 247.9 ± 60.1* |
| Pulmonary vascular resistance (dyne·sec/cm5) | |||||
| Group 1 | 82.4 ± 20.0 | 59.6 ± 14.4 | 56.0 ± 13.5 | 54.5 ± 13.2 | 74.4 ± 18.0 |
| Group 2 | 61.7 ± 14.9 | 31.3 ± 7.6* | 37.1 ± 9.0* | 33.1 ± 8.0* | 25.2 ± 6.1* |
Group I: general anesthesia;
Group II: combined general anesthesia and HTEA with levobupivacaine;
t1: preoperatively;
t2: after separation from cardiopulmonary bypass;
t3: arrival in the intensive care unit;
t4: 6 hours after arrival in the intensive care unit;
t5: 24 hours after arrival in the intensive care unit;
∗ P < 0.05: significant difference between Group I and Group II;
+ P < 0.05: significant difference between the values when compared with t1 value within the groups.
The malondialdehyde and total antioxidant capacity levels.
| Parameters | t1 | t2 | t3 | t4 |
|---|---|---|---|---|
| Median (range) | Median (range) | Median (range) | Median (range) | |
| Malondialdehyde ( | ||||
| Group 1 | 1.53 (0.74–3.51) | 1.49 (0.99–3.32) | 1.88 (1.14–5.20) | 2.33 (1.44–4.85)+ |
| Group 2 | 1.39 (0.74–2.67) | 1.58 (0.99–2.97)∗+ | 2.18 (1.24–5.40)∗+ | 2.48 (1.34–5.40)∗+ |
| Total antioxidant capacity | ||||
| Group 1 | 2.11 (1.84–2.32) | 2.02 (1.71–2.14)+ | 1.49 (0.33–1.77) | 1.57 (1.23–1.78) |
| Group 2 | 2.05 (1.25–2.46) | 1.95 (1.59–2.19)+ | 1.47 (1.30–1.83)∗+ | 1.59 (1.12–1.91)* |
P < 0.05: significant difference between Group I and Group II;
+ P < 0.05: significant difference between the values when compared with t1 value within the groups.
Figure 1Comparison of troponin values between groups; ∗ P < 0.05. Group I: general anesthesia, Group II: combined general anesthesia and HTEA with levobupivacaine, troponin 1: preoperatively, troponin 2: 6 hours after arrival in the intensive care unit, and troponin 3: 24 hours after arrival in the intensive care unit.
Figure 2Comparison of CK-MB values between groups; ∗ P < 0.05. Group I: general anesthesia, Group II: combined general anesthesia and HTEA with levobupivacaine, CK-MB 1: preoperatively, CK-MB 2: 6 hours after arrival in the intensive care unit, and CK-MB3: 24 hours after arrival in the intensive care unit.
Figure 3Comparison of VAS values between groups; ∗ P < 0.05. Group I: general anesthesia, Group II: combined general anesthesia and HTEA with levobupivacaine, VAS: visual analog scale, VAS 0: arrival in the intensive care unit, VAS 4: 4 hours after arrival in the intensive care unit, VAS 8: 8 hours after arrival in the intensive care unit, VAS 12: 12 hours after arrival in the intensive care unit, VAS 16: 16 hours after arrival in the intensive care unit, VAS 20: 20 hours after arrival in the intensive care unit, and VAS 24: 24 hours after arrival in the intensive care unit.